Diagnostic and prognostic values of FDG-PET in patients with non-small cell lung cancer

Clinical Imaging

Volumn 33, Issue 2, 2009, Pages 90-95

  Abe, Koichiro ^a   Baba, Shingo ^a   Kaneko, Koichiro ^a   Isoda, Takuro ^a   Yabuuchi, Hidetake ^a   Sasaki, Masayuki ^a   Sakai, Shuji ^a   Yoshino, Ichiro ^a   Honda, Hiroshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

FDG PET; Non small cell lung cancer; Prognosis; Staging; SUV

Indexed keywords

FDG-PET; NON-SMALL CELL LUNG CANCER; PROGNOSIS; STAGING; SUV;

BIOLOGICAL ORGANS; DECISION MAKING; DIAGNOSIS; DIAGNOSTIC RADIOGRAPHY; GLUCOSE; MEDICAL IMAGING; MULTIVARIANT ANALYSIS; POSITRON ANNIHILATION SPECTROSCOPY; TOMOGRAPHY;

POSITRON EMISSION TOMOGRAPHY;

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS;

EID: 60349087400     PISSN: 08997071     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinimag.2008.06.032     Document Type: Article

References (22)

1. Annual Statistical Report of National Health Conditions. Health and welfare statistics association. Tokyo, Japan: Japanese Ministry of Health and Welfare. p. 48.
2. Brundage M.D., Davies D., and Mackillop W.J. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122 (2002) 1037-1057
3. Strauss L.G., Clorius J.H., Schlag P., Lehner B., Kimmig B., Engenhart R., et al. Recurrence of colorectal tumors: PET evaluation. Radiology 170 (1989) 329-332
4. 18F]-fluoro-2-deoxy-d-glucose. Radiology 197 (1995) 135-139
5. Crippa F., Agresti R., Seregni E., Greco M., Pascali C., Bogni A., et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 39 (1998) 4-8
6. Silvestri G.A., Tanoue L.T., Margolis M.L., Barker J., Detterbeck F., and American College of Chest Physicians. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest 123 Suppl. 1 (2003) 147S-156S
7. Baum R.P., Hellwig D., and Mezzetti M. Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer. Q J Nucl Med Mol Imaging 48 (2004) 119-142
8. Shim S.S., Lee K.S., Kim B.T., Chung M.J., Lee E.J., Han J., et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 236 (2005) 1011-1019
9. Birim O., Kappetein A.P., Stijnen T., and Bogers A.J. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg 79 (2005) 375-382
10. Takamochi K., Yoshida J., Murakami K., Niho S., Ishii G., Nishimura M., et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer 47 (2005) 235-242
11. 18F-FDG PET versus nodule-enhancement CT. Am J Roentgenol 187 (2006) 1361-1367
12. Kramer H., Post W.J., Pruim J., and Groen H.J. The prognostic value of positron emission tomography in non-small cell lung cancer: analysis of 266 cases. Lung Cancer 52 (2006) 213-217
13. Duhaylongsod F.G., Lowe V.J., Patz E.F., Vaughn A.L., Coleman R.E., and Wolfe W.G. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 60 (1995) 1348-1352
14. Vesselle H., Schmidt R.A., Pugsley J.M., Li M., Kohlmyer S.G., Vallires E., et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 6 (2000) 3837-3844
15. Ahuja V., Coleman R.E., Herndon J., and Patz E.F. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 83 (1998) 918-924
16. Eschmann S.M., Friedel G., Paulsen F., Reimold M., Hehr T., Budach W., et al. Is standardised (18)F-FDG uptake value an outcome predictor in patients with Stage III non-small cell lung cancer?. Eur J Nucl Med Mol Imaging 33 (2006) 263-269
17. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 43 (2002) 39-45
18. 18F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic Stage I lung adenocarcinoma. Cancer 107 (2006) 2468-2473
19. Davies A., Tan C., Paschalides C., Barrington S.F., O'Doherty M., Utley M., et al. FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. Lung Cancer 55 (2007) 75-78
20. Downey R.J., Akhurst T., Gonen M., Vincent A., Bains M.S., Larson S., et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22 (2004) 3255-3260
21. 18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 17 (1999) 3201-3206
22. 18F]Fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23 (2005) 1136-1143